Application and progress of biological agents in IgA nephropathy
IgA nephropathy is the most common primary glomerular disease in the world.Currently,there is no recognized standardized treatment for IgA nephropathy with high risk of disease progression.Symptomatic treatment and combined drug treatment are commonly used in clinical practice to protect renal function and delay disease progression.At present,the therapeutic drugs for IgA nephropathy are still relatively scarce.Biological agents provide a new idea for IgA nephropathy treatment.The biological agents not only reduce the side effects of long-term glucocorticoids and immunosuppressive therapy,but also improve the prognosis of patients with IgA nephropathy to a certain extent.At present,many clinical trials of biological agents are being carried out.This article reviews the application and progress of biological agents in IgA nephropathy,and provides reference for the treatment of IgA nephropathy.
NETL
NSTL
万方数据
